newsfilter
← Latest News
GlobeNewswire·

FibroBiologics Advances Patient Dosing for Phase 1/2 Clinical Trial of CYWC628 for the Treatment of Diabetic Foot Ulcers

  • FibroBiologics announced that the first patients were dosed in its Phase 1/2 clinical trial for CYWC628 to treat diabetic foot ulcers during the week of June 1, 2026.
  • Drug product from the company's second good manufacturing practice (GMP) run has been released & is scheduled to ship to Australia during the week of June 15, 2026.
  • The company completed manufacturing for the first two batches of its third GMP run of CYWC628.
  • CYWC628 is an investigational topically administered allogeneic fibroblast cell therapy designed to restore underlying biology for chronic wound healing rather than just managing symptoms.
  • The clinical trial is a prospective, multicenter, randomized study evaluating safety, tolerability, & efficacy using either standard of care plus low or high-dose CYWC628 or standard of care only over up to 12 weeks.
  • FibroBiologics holds 270+ issued & pending patents covering various clinical pathways including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, & cancer.